Abiopharma

🔍 Goodwin William Carroll Murphy (Executive)

Company: Oklo Inc. (OKLO)

Report Date: 2026-03-24

Detailed Transactions and Holdings:

• Acquired 20,685 shares of Class A Common Stock (Direct)
  Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 36,676.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 10,639 shares of Class A Common Stock at $56.48 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 26,037.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 20,685 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 166,758.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 24, 2026, 20,685 RSUs were released to the Reporting Person.
• F2: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of the RSUs listed in Table II. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: On August 12, 2024, the Reporting Person was granted 248,227 RSUs, vesting as to one-third of the underlying shares on August 12, 2025 and thereafter in eight substantially equal quarterly installments.